1. Home
  2. CMC vs TGTX Comparison

CMC vs TGTX Comparison

Compare CMC & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Commercial Metals Company

CMC

Commercial Metals Company

N/A

Current Price

$66.31

Market Cap

6.9B

Sector

Industrials

ML Signal

N/A

Logo TG Therapeutics Inc.

TGTX

TG Therapeutics Inc.

HOLD

Current Price

$54.27

Market Cap

7.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CMC
TGTX
Founded
1915
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Steel/Iron Ore
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.9B
7.9B
IPO Year
1994
2008

Fundamental Metrics

Financial Performance
Metric
CMC
TGTX
Price
$66.31
$54.27
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
9
5
Target Price
$73.33
$49.80
AVG Volume (30 Days)
1.0M
2.2M
Earning Date
03-26-2026
05-04-2026
Dividend Yield
1.20%
N/A
EPS Growth
N/A
1746.67
EPS
3.96
0.17
Revenue
$7,918,430,000.00
$2,785,000.00
Revenue This Year
$18.81
$49.08
Revenue Next Year
$6.34
$26.69
P/E Ratio
$16.48
$297.41
Revenue Growth
25.57
N/A
52 Week Low
$53.08
$26.76
52 Week High
$84.87
$59.30

Technical Indicators

Market Signals
Indicator
CMC
TGTX
Relative Strength Index (RSI) 41.27 59.92
Support Level $58.18 $51.22
Resistance Level $72.94 $58.08
Average True Range (ATR) 2.49 2.10
MACD -0.82 0.39
Stochastic Oscillator 10.25 80.70

Price Performance

Historical Comparison
CMC
TGTX

About CMC Commercial Metals Company

Commercial Metals Co is a manufacturer and supplier of early-stage construction materials, including steel reinforcing bars, concrete pipes, precast products, and soil stabilization solutions. It also produces merchant bar, steel fence posts, and wire rod, serving domestic and some international markets in Europe and Asia. Its products are used in infrastructure and building projects such as highways, bridges, airports, and commercial and residential buildings.

About TGTX TG Therapeutics Inc.

TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.

Share on Social Networks: